TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer

Journal:

Journal of Thoracic and Cardiovascular Surgery

Published:

2026-01-01

DOI:

10.1016/j.jtcvs.2025.09.017

Affiliations:

15

Authors:

14

Go to article

Institutions	Authors	Share
AstraZeneca Canada Inc., Canada	2.000000	0.14
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.07
University Hospital Zurich (UHZ), Switzerland	1.000000	0.07
Duke University Hospital, United States of America (USA)	1.000000	0.07
UCLA Jonsson Comprehensive Cancer Center, United States of America (USA)	1.000000	0.07
Royal Brompton Hospital, United Kingdom (UK)	1.000000	0.07
Kindai University, Japan	1.000000	0.07
Yale University, United States of America (USA)	1.000000	0.07
AstraZeneca, United Kingdom (UK)	1.000000	0.07
AstraZeneca Cambridge, United Kingdom (UK)	1.000000	0.07
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.07
Duke-NUS Medical School, Singapore	0.500000	0.04
National Cancer Centre Singapore (NCCS), Singapore	0.500000	0.04
VA Nebraska-Western Iowa Health Care System, United States of America (USA)	0.500000	0.04
University of Nebraska Medical Center (UNMC), United States of America (USA)	0.500000	0.04

Interested in Oncology and Carcinogenesis?